GMT.WA

Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.